SecBot SecBot
DEFA14A ·Filed Jun 1, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001213900-26-063170
Proxy solicitation materials
Actionable Insight • Neutral

Monitor vote outcome; management is expected to prevail given low dissident ownership (~0.7%). If dissidents gain any seats, watch for operational disruption. Post-meeting, focus on BARDA Phase 2b COVID trial progress and cash runway into Q2 2027.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6300
T+0 close · Jun 1, 2026 · via day close
Latest settled
−20.63%
T+60 · $0.5000
Vs SPY
−21.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $0.6300entry
  2. T+1 · 6mo ago −3.97%α −4.12% · $0.6050
  3. T+5 · 5mo ago −1.59%α +1.16% · $0.6200
  4. T+20 · 5mo ago −4.76%α −3.46% · $0.6000
  5. T+60 · 3mo ago −20.63%α −21.87% · $0.5000

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart filed definitive additional proxy materials urging shareholders to vote FOR its six director nominees at the July 16, 2026 annual meeting, opposing a dissident group led by Daniel P. Houle that nominated three candidates. Management emphasizes the dissidents' lack of biotech experience and highlights CEO Steve Lo's role in securing BARDA funding and partnerships. The outcome likely favors the board given the dissidents' ~0.7% stake.

Key Financial Metrics

Vote
director election
Meeting
2026-07-16
Seats Contested
3

Key Facts

  • Annual meeting scheduled for July 16, 2026.
  • Board recommends voting FOR all six management nominees, WITHHOLD on dissident slate.
  • Dissident stockholder Daniel P. Houle nominated three candidates with no biotech board experience.
  • CEO Steve Lo negotiated BARDA award up to $453M and a $25M share purchase agreement.
  • Average director tenure is 2.3 years; board recently refreshed.

Financial Impact

No new financial figures disclosed; BARDA award valued up to $453 million and $25 million share purchase agreement referenced as prior achievements.

Risk Factors

  • Dissident slate could win seats if retail vote is swayed, potentially disrupting clinical and partnership momentum.
  • Proxy contest may distract management from advancing key milestones.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-063170
Document: 0001213900-26-063170-index-headers.html0001213900-26-063170
Document: 0001213900-26-063170-index.html0001213900-26-063170
Document: 0001213900-26-063170.txt0001213900-26-063170

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026